The Enterprise Value as of November 2024 (TTM) for Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) is 154.95B

According to Bristol-Myers Squibb Company PFD CONV 2’s latest financial reports and current stock price. The company's current Enterprise Value is 154.95B. This represents a change of -91.49% compared to the average of 1.82T of the last 4 quarters.

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Historical Enterprise Value (quarterly & annually)

How has BMYMP Enterprise Value performed in the past?

The mean historical Enterprise Value of Bristol-Myers Squibb Company PFD CONV 2 over the last ten years is 1.99T. The current 154.95B Enterprise Value has changed 678.60% with respect to the historical average. Over the past ten years (40 quarters), BMYMP's Enterprise Value was at its highest in in the March 2023 quarter at 2.55T. The Enterprise Value was at its lowest in in the September 2019 quarter at 1.33T.

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Bristol-Myers Squibb Company PFD CONV 2 Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Average Enterprise Value

How has BMYMP Enterprise Value performed in the past?

The current Enterprise Value of Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Enterprise Value vs. Peers

How is BMYMP’s Enterprise Value compared to its peers?

Bristol-Myers Squibb Company PFD CONV 2’s Enterprise Value is less than Novartis AG (224.41B), less than Astellas Pharma Inc. (0), less than Roche Holding AG (3.73T), less than Astellas Pharma Inc. (250.10B), less than Daiichi Sankyo Company, Limited (3.88T), less than AstraZeneca PLC (8.99T), less than Otsuka Holdings Co., Ltd. (247.43B), less than Chugai Pharmaceutical Co., Ltd. (4.87T), less than Roche Holding AG (11.54T), less than GSK plc (251.81B), greater than Novartis AG (54.93B), less than Sanofi (232.94B), greater than AstraZeneca PLC (138.92B), less than null (248.09B),

Build a custom stock screener for Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Bristol-Myers Squibb Company PFD CONV 2 using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Bristol-Myers Squibb Company PFD CONV 2 or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.